Pursuing Parkinson’s Disease Gene Therapies: Strategies & Operational Requirements, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speakers from Premier Research will discuss alternate gene therapies such as opto- and chemogenetics and novel genome-editing technology as well as the use of engineered, non-replicating viral vectors, predominantly recombinant adeno-associated virus or lentivirus. Attendees will learn how to meet the requirements for surgical techniques and equipment when performing intra-CNS administration of viral vectors and operational considerations for Parkinson’s disease gene therapy studies.

...these studies face unique challenges due to their patient population and the complex regulatory considerations for these advanced therapies.

While treatment of Parkinson’s disease (PD) has traditionally been limited to dopamine replacement therapy to alleviate symptoms, gene therapy studies have recently evaluated both non-disease-modifying and disease-modifying transgenes for PD treatment, with encouraging results.

Non-disease-modifying therapies have improved symptomatology and disease-modifying strategies, including stopping PD-mediated cell death and/or regenerating lost neurons, and show potential in slowing disease progression. However, these studies face unique challenges due to their patient population and the complex regulatory considerations for these advanced therapies.

Conducting these trials requires careful attention to investigator and site selection and adherence to local regulatory and protocol design requirements. The need for long-term patient follow-up, potentially as long as 15 years, puts added demands on patients and sites.

Join expert speakers from Premier Research, Andreas Schreiner, M.D., Vice President, Medical Affairs Neuroscience and Analgesia; and Hanna Wide, M.S., Executive Director, Cell and Gene Therapy, in a live webinar on Wednesday, April 14, 2021 at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Pursuing Parkinson’s Disease Gene Therapies: Strategies & Operational Requirements.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Sydney Perelmutter
Tel: +1 (416) 977-6555 x 352
Email: sperelmutter@xtalks.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
(416) 977-6555 x352
Email >
Visit website